Business Information
The group's principal activities are to develop, manufacture and market selected therapeutic and diagnostic products. The group's operating segments are divided into health products and therapeutic development. As of 31-Dec-2002, the group derived revenues from the health products segment. Under the health products segment, the group markets research and commercial diagnostic assays and fine chemicals to research and clinical laboratories and other customers. The therapeutic products segment is focused on the development of new drugs to treat diseases associated with tissue damage from free radicals and reactive oxygen species. The group markets its products in the United States, the United Kingdom, France, Germany, Japan, Spain, Korea, China and other countries.
|
|
Name |
Title
|
Email
|
| Marvin Hausman | Chmn., CEO, Pres. | N/A | | Gary Post | Dir., Acting COO | N/A | | Colin Neill | Dir., Sec. | N/A | | John Repine | Dir. | N/A | | Matthew Spolar | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 5,776 | (4,940) | | 2005 | 2,497 | (3,109) | | 2004 | 2,364 | (2,698)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
